FerroKin BioSciences Announces Start of a Phase 2 Clinical Trial of FBS0701 as a Novel Treatment for Transfusional Iron Overload

Published: Sep 09, 2010

SAN FRANCISCO, Sept. 9, 2010 (GLOBE NEWSWIRE) -- FerroKin BioSciences today announced the initiation of an international Phase 2 study of FBS0701, a novel once-daily iron chelator in development for the treatment of transfusional iron overload. The Phase 2 study will assess the safety, tolerability, and pharmacodynamics of FBS0701.

Back to news